Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120874 · ClinicalTrials.gov registry record · Phase 4
Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00120874 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 20 participants.
The verdict
NCT00120874, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
Interventions
- DRUG Memantine
- BEHAVIORAL Individualized management of AD including caregiver training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-08 |
| Est. Completion | 2011-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00120874
The ClinicalTrials.gov registry entry for NCT00120874 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Memantine is the first listed.
NCT00120874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00120874 about?
NCT00120874 is a clinical study titled "Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training". The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
What is the current status of trial NCT00120874?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2006-08. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00120874?
The interventions under investigation include: Memantine (DRUG), Individualized management of AD including caregiver training (BEHAVIORAL).
Who is sponsoring clinical trial NCT00120874?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.